Mortality-Related Risk Factors for Coronavirus Disease (COVID-19)-Associated Mucormycosis: a systematic review and meta-analysis.
Autor: | Ostovan VR; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Tabrizi R; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.; Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran., Bazrafshan H; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Bahrami Z; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Khazraei H; Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Khazraei S; Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran., Borhani-Haghighi A; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Moghadami M; Clinical Microbiology Research Center, Shiraz University of Medical sciences, Shiraz, Iran., Grant M; Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT 06520 United States. |
---|---|
Jazyk: | angličtina |
Zdroj: | Current fungal infection reports [Curr Fungal Infect Rep] 2022; Vol. 16 (4), pp. 143-153. Date of Electronic Publication: 2022 Aug 11. |
DOI: | 10.1007/s12281-022-00440-2 |
Abstrakt: | Purpose of Review: Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) can increase the susceptibility of individuals to contracting mucormycosis through several mechanisms. Nowadays, coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a serious public health concern, particularly in developing countries. This meta-analysis aims to identify the risk factors that affect the mortality rate of patients with CAM. Recent Findings: We systematically searched PubMed, Google Scholar, Scopus, Cochrane library, and preprint databases using pertinent keywords and the reference lists of the included relevant articles from inception till October 27, 2021. In order to reduce the effects of small-scale studies, we only selected cross-sectional, case-control, and cohort studies and case series with at least four patients. We identified 26 articles that included 821 patients with CAM. The effect size (ES) of mortality rate was 28% (95% confidence interval (CI) 20%-38%; I 2 =82.28%; p for Cochran Q<0.001). The CAM patients with a history of comorbidities other than diabetes (malignancies, transplant, or renal failure), mechanical ventilation due to COVID-19, pulmonary and cerebral mucormycosis, and those who only received medical treatment for mucormycosis had the highest mortality rate. Summary: Coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a major public health problem, particularly in developing countries. Severe COVID-19 infection, history of mechanical ventilation, early CAM, comorbidities other than diabetes (malignancies, transplant, or renal failure), pulmonary and rhino-orbito-cerebral mucormycosis, and delivering only medical treatment for mucormycosis were the worst prognostic factors in CAM patients. Identifying the mortality-related risk factors in CAM patients may help reduce the mortality rate by implementing optimized treatment approaches. Supplementary Information: The online version contains supplementary material available at 10.1007/s12281-022-00440-2. Competing Interests: Conflict of InterestThe authors declare no conflicts of interest. (© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.) |
Databáze: | MEDLINE |
Externí odkaz: |